Acute Myeloid Leukemia (AML)
What is the concern behind PARP inhibitors and leukemia?
Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.
For adults with relapsed or refractory AML who have an IDH2 genetic mutation
Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.
The site of cancer care may partially explain survival differences between children and AYAs with ALL.
Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.
Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.
Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.
Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.
Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).
First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.
A simple blood test can identify post-chemo patients with the NPM1 gene mutation.
Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.
Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid LeukemiaDecember 06, 2015
The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
A molecule isolated from sea sponges and later synthesized can halt the growth of cancerous cells, opening the door to a new treatment for leukemia.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|